We selected MIF and the Type I IFN pathway for the current investigation based on the fact that MIF and Type I IFN have each been demonstrably associated with the pathogenesis of SLE in both murine and human studies, and are the subject of clinical trials in SLE. The gene discussed is MIF; the disease is systemic lupus erythematosus.